Resonetics® Invests in Nitinol Gun Drilling Capabilities Through Purchase of Assets from Medical Component Specialists | CG Stock News

Author's Avatar
May 19, 2025
Article's Main Image
  • Resonetics strengthens its nitinol operations with the acquisition of gun drilling assets from Medical Component Specialists.
  • The purchase enhances Resonetics' control over its supply chain and reduces lead times for medical device production.
  • This move aligns with the company's broader strategy of establishing a comprehensive nitinol portfolio in the industry.

Resonetics has announced the acquisition of nitinol gun drilling operations and associated assets from Medical Component Specialists' facility in New Boston, NH. This strategic move is part of Resonetics' expansion in the U.S.-based nitinol sector, focusing on reinforcing their supply chain and improving material availability and lead times for the production of medical devices.

Gun drilling, a precise machining process, is crucial in creating high-performance nitinol tubing, which is essential for cutting-edge medical devices. By acquiring and integrating this capability, Resonetics enhances its ability to support its premium tubing initiative while minimizing supply chain risks.

This acquisition is a continuation of Resonetics' previous efforts in the nitinol industry, which included investments in melt capacity, raw materials, and the acquisition of Memry Corp. and SAES Smart Materials. These steps have helped Resonetics establish one of the most extensive nitinol portfolios in the industry, enabling them to maintain a competitive edge in providing open-source supplies to OEMs and contract manufacturers in the medical device market.

Kevin Kelly, CEO of Resonetics, emphasized the importance of this investment in bolstering the company's position to deliver quality and innovative solutions quickly, further supporting breakthroughs in the medical device industry.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.